Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates (FABACs). Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis (NASH), a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance.

Investment goal date:
Dividends reinvested
Galmed Pharmaceuticals Ltd. GLMD report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-26
--
--
Q3 2017
2017-11-06
--
--
Q2 2017
2017-07-31
-0.2200
-0.2200
Q1 2017
2017-05-15
-0.2600
-0.2600
Q4 2016
2017-03-23
-0.4000
-0.4000
Q3 2016
2016-11-07
-0.3400
-0.3400
Q2 2016
2016-08-03
-0.3900
-0.3900
Q1 2016
2016-05-16
-0.3600
-0.3600
Q4 2015
2016-03-22
-0.2900
-0.2900
Q3 2015
2015-11-09
-0.2300
-0.2300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
683 Capital Management, LLC
500000
CapWealth Advisors, LLC
12000
KCG Holdings, Inc.
20473
MORGAN STANLEY
56103
P.A.W. CAPITAL CORP
120000
Park West Asset Management LLC
205500
REILLY FINANCIAL ADVISORS, LLC
250
ROYAL BANK OF CANADA
4
WELLS FARGO & CO/MN
5000
Major Shareholders
Name Relationship
Total Shares
Holding stocks